Anti-angiogenic therapy at the time of immunological therapy for lung cancer of non-small cells with histological findings of adenocarcinoma

Abstract:

Lung cancer is one of the most common malignancies, while most cases are diagnosed with adenocarcinoma. Treatment methods depend on the stage of the disease, the biological characteristics of the tumor and the general condition of the patient and include surgery, systemic cytostatic treatment, radiotherapy, targeted therapy and immunotherapy (checkpoint inhibitors). Following disease progression to checkpoint inhibitors treatment option is combination of docetaxel and nintedanib. Nintedanib is a triple angiokinase inhibitor that blocks the kinase activity of vascular endothelial growth factor receptor, platelet growth factor receptor and fibroblast growth factor receptor. Data on safety and efficacy were obtained in two large clinical trials, LUME-Lung-1 and VARGADO, which showed that treatment with nintedanib and docetaxel, after progression to line 1 treatment (chemotherapy or a combination of immunotherapy and chemotherapy), had clinically significant efficacy and good safety profile in patients with lung adenocarcinoma.

Key words:
immunotherapy; angiogenesis inhibitors; lung neoplasms; NSCLC